Pierre Fabre Laboratories and RedRidge Bio Announce a Drug Discovery and Co-development Partnership
CASTRES, France, CAMBRIDGE, Massachusetts and BASEL, Switzerland, March 12, 2025 /PRNewswire/ -- Pierre Fabre Laboratories and RedRidge Bio ('RedRidge') today announced an exclusive R&D collaboration and license agreement to identify and develop biparatopic antibody (BPA) drug candidates against multiple targets. In line with Pierre Fabre Laboratories' innovation strategy, the partnership's therapeutic focus will be on precision oncology as well as dermatology and rare diseases.
Under the terms of the agreement, RedRidge will provide its capabilities to engineer, screen and characterize BPAs against an undisclosed portfolio of jointly nominated targets, while Pierre Fabre Laboratories will provide their drug development expertise to help drive two co-development programs through clinical development. RedRidge will hold exclusive commercial rights in the United States, Canada, and Japan for both programs, while Pierre Fabre Laboratories will hold exclusive rest-of-world rights. In addition, Pierre Fabre Laboratories will hold exclusive worldwide rights for a third program after a hand-off by RedRidge at a preclinical stage.
Financial terms of the agreement are not disclosed but include investment participation by Pierre Fabre Laboratories in RedRidge's Series A financing that will be announced separately, as well as upfront, milestone and future sales royalty payments in addition to funded research payments for Pierre Fabre Laboratories' worldwide program. RedRidge and Pierre Fabre Laboratories will share R&D costs for the co-development programs.
'This strategic alliance attests to the RedRidge team's expertise in innovation and drug discovery for a wide variety of therapeutic targets. We are thrilled to join forces with Pierre Fabre Laboratories as a highly experienced development partner and look forward to building a long-term partnership that synergistically leverages the capabilities of each company,' said Alex Mayweg, PhD, chairperson of RedRidge's board and a managing director at Versant Ventures.
'Pierre Fabre Laboratories are excited to enter into this agreement with RedRidge, which confirms our commitment to collaborate with innovative biotechnology companies. This partnership will allow us to capitalize on RedRidge's cutting-edge expertise in biparatopic antibody drug discovery to deliver high quality clinical candidates on multiple targets addressing oncology, dermatology and rare diseases. It represents a significant milestone in the implementation of our strategy to enrich further our R&D pipeline,' stated Francesco Hofmann, PhD, Head of Research and Development for Medical Care at Pierre Fabre Laboratories.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 hours ago
- Yahoo
Vivani Medical Appoints Anthony Baldor as Chief Financial Officer
ALAMEDA, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) ('Vivani' or the 'Company'), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the appointment of Anthony Baldor as Chief Financial Officer. Baldor succeeds Brigid A. Makes, who has decided to retire from Vivani to focus on her board appointments and personal projects after a distinguished career and significant contributions to the Company. Baldor brings more than 20 years of financial management experience in the biotechnology sector, with a proven record in fundraising, business development and corporate strategy. Prior to joining Vivani, Baldor was Chief Financial Officer at Diakonos Oncology Corp., where he led the company's Series Seed and Series A financings, and Vice President of Corporate Strategy & Development at 4D Molecular Therapeutics, Inc., where he played a pivotal role in the company's Series C financing, initial public offering and various key partnership activities. His experience also includes positions at Jefferies Group LLC, BioInnovation Capital, LLC, RMI Partners, and Cequent Pharmaceuticals, Inc. Baldor holds both an M.B.A. and a Master of Data Science from the University of California, Berkeley, and a B.A. from Vassar College. 'Anthony's deep expertise in financial strategy will be instrumental as Vivani advances its pipeline and scales its operations,' said Vivani Chief Executive Officer Adam Mendelsohn, PhD. 'We are excited to welcome him to the leadership team at this pivotal time for the Company.' Dr. Mendelsohn continued: 'On behalf of the Board and the entire Vivani team, I thank Brigid for her outstanding leadership and dedication. Her expertise and vision have been invaluable to our growth and success. This includes helping guide our company through a transformative period, including the successful completion of the merger of Nano Precision Medical and Second Sight Medical Products, and the advancement of our clinical and commercial strategy.' Makes will continue to serve in an advisory capacity during the transition. About Vivani Medical, Inc. Leveraging its proprietary NanoPortal™ platform, Vivani develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and potentially to improve patient tolerance to their medication. Vivani's lead program, NPM-115, is a six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in obese or overweight patients. Vivani's emerging pipeline includes NPM-139 (semaglutide implant), which is also under development for chronic weight management. The semaglutide implant has the added potential benefit of once-yearly administration. NPM-119 refers to the Company's six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the challenges associated with the daily or weekly administration of oral and injectable medications. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately 50%, including those taking daily pills. Medication non-adherence, which contributes to more than $500 billion in annual avoidable healthcare costs and 125,000 potentially preventable deaths annually in the U.S. alone, is a primary and daunting reason obese or overweight patients, and patients taking type 2 diabetes or other chronic disease treatments, face significant challenges in achieving positive real-world effectiveness. While the current GLP-1 landscape includes over 50 new molecular entities under clinical stage development, Vivani is confident that its highly differentiated portfolio of miniature, ultra long-acting GLP-1 implants have the potential to provide an attractive therapeutic option for patients, prescribers and payers. For more information, please visit: Forward-Looking Statements This press release contains certain 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: 'target,' 'believe,' 'expect,' 'will,' 'may,' 'anticipate,' 'estimate,' 'would,' 'planned,' 'positioned,' 'potential,' 'future,' 'allow,' 'intended' and other similar expressions that are in this press release, including statements regarding Vivani's business, products in development, including the therapeutic potential thereof, the planned development therefor, the completion of the LIBERATE-1™ trial and reporting of trial results, Vivani's development plans for Vivani's products, including NPM-115, NPM-139, NPM-119, and Vivani's plans with respect to Cortigent, Inc. ('Cortigent'), a wholly owned subsidiary of the Company, and its proposed spin-off, technology, strategy, cash position and financial runway. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Vivani's current beliefs, expectations, and assumptions. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including, without limitation, risks that the spin-off will not be completed in a timely manner or at all; risks of failure to satisfy any conditions to the spin-off; risks of failure of the spin-off to qualify for non-recognition of gain or loss for U.S. Federal Income Tax purposes, and approval with the U.S. Securities and Exchange Commission ('SEC') and Nasdaq; uncertainty of whether the anticipated benefits of the spin-off can be achieved; risks of unexpected costs or delays; and risks and uncertainties associated with the development and commercialization of products and product candidates that may impact or alter anticipated business plans, strategies and objectives. Because forward-looking statements relate to the future, they are subject to additional inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani's control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, risks related to the development and commercialization of Vivani's products, including NPM-115, NPM-139, and NPM-119; delays and changes in the development of Vivani's products, including as a result of applicable laws, regulations and guidelines, potential delays in submitting and receiving regulatory clearance or approval to conduct Vivani's development activities; risks related to the initiation, enrollment and conduct of Vivani's planned clinical trials and the results therefrom; Vivani's history of losses and Vivani's ability to access additional capital or otherwise fund Vivani's business; market conditions and the ability of Cortigent to complete its spin-off, Cortigent's history of losses and its ability to access additional capital or otherwise fund Cortigent's business and advance its product candidates and pre-clinical programs. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. There may be additional risks that the Company and Cortigent consider immaterial, or which are unknown. A further list and description of risks and uncertainties can be found in the Company's most recent Annual Report on Form 10-K filed with the SEC on March 31, 2025, as updated by the Company's subsequent Quarterly Reports on Form 10-Q and in other reports that the Company has filed with the SEC. Any forward-looking statements made by Vivani or Cortigent in this press release are based only on information currently available to the Company and Cortigent and assumptions that Vivani and Cortigent believe to be reasonable. Any forward-looking statement speaks only as of the date on which it is made. Neither the Company nor Cortigent undertake any obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time-to-time, whether as a result of added information, future developments or otherwise, except as required by law. Company Contact:Donald DwyerChief Business Officerinfo@ 506-8462 Investor Relations Contact:Jami TaylorInvestor Relations Advisorinvestors@ 506-8462 Media Contact:Sean LeousICR 866-4012Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
ABRDN INCOME CREDIT STRATEGIES FUND 5.25% SERIES A PERPETUAL PREFERRED SHARES DECLARE QUARTERLY DIVIDEND
PHILADELPHIA, June 10, 2025 /PRNewswire/ -- The Board of Trustees of abrdn Income Credit Strategies Fund (the "Fund"), has declared a cash distribution of $0.328125 per share of the Fund's 5.250% Series A Perpetual Preferred Shares (NYSE: ACP PRA) ("Series A Preferred Shares"). The distribution is payable on June 30, 2025, to holders of Series A Preferred Shares of record on June 20, 2025 (ex-dividend date June 20, 2025). The Series A Preferred Shares trade on the NYSE under the symbol "ACP PRA", are rated "A2" by Moody's Investors Service and have an annual dividend rate of $1.3125 per share. The Series A Preferred Shares were issued on May 10, 2021, at $25.00 per share and pay distributions quarterly. Distributions may be paid from sources of income other than ordinary income, such as net realized short-term capital gains, net realized long-term capital gains and return of capital. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund's investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. In January 2026, a Form 1099-DIV will be sent to shareholders, which will state the amount and composition of distributions and provide information with respect to their appropriate tax treatment for the 2025 calendar year. You should not draw any conclusions about the Fund's investment performance from the amount of this distribution. Aberdeen Investments Global is the trade name of Aberdeen's investments business, herein referred to as "Aberdeen Investments" or "Aberdeen". In the United States, Aberdeen Investments refers to the following affiliated, registered investment advisers: abrdn Inc., abrdn Investments Limited, and abrdn Asia Limited. Closed-end funds are traded on the secondary market through one of the stock exchanges. A Fund's investment return and principal value will fluctuate so that an investor's shares may be worth more or less than the original cost. Shares of closed-end funds may trade above (a premium) or below (a discount) the net asset value (NAV) of the fund's portfolio. There is no assurance that a Fund will achieve its investment objective. Past performance does not guarantee future results. View original content to download multimedia: SOURCE abrdn Income Credit Strategies Fund 5.25% Series A Perpetual Preferred Shares
Yahoo
3 days ago
- Yahoo
Tri-Cities at rising risk for blackouts. But $100M Badger Canyon project draws concerns
The Bonneville Power Administration is proposing a $107 million transmission project for the Tri-Cities area that would help solve two problems — the Tri-Cities growing risk of blackouts and the lack of electricity available to attract new industry. Construction could start as soon as spring 2026 on the project just south of the Tri-Cities. It would increase BPA's transmission capacity in the greater Tri-Cities area by 66%. The 18-mile long, 115-kilovolt transmission line would start at the Badger Canyon Substation on West Clearwater Avenue, and be built through Badger Canyon south of Richland, Then it would go through Webber Canyon in the Horse Heaven Hills and west to a proposed Webber Canyon Substation near County Well Road. The only part of its route not yet decided is a stretch just south of Richland where some farmers and homeowners are concerned it would be built too close to their homes or require some of their land. 'This line is all about making sure there's sufficient transmission capacity to keep the lights on in the Tri-Cities area,' said Jeff Cook, an acting BPA vice president, in a statement. 'It also would help local utilities keep pace with growth and provide electric service to new and existing end-use customers.' Now the transmission lines that bring power into the Tri-Cities are at risk of becoming overloaded during periods of high electricity use, leading to potential black outs in the area, according to BPA. When loads surpass 1,100 megawatts in BPA's Tri-Cities service area — which includes Benton, Franklin, Walla Walla and Grant counties — a single transmission line outage can cause system operating limits to be exceeded, which can lead to a loss of power. Loads in the Tri-Cities area have surpassed 1,100 megawatt on hot days every summer for the past 10 years, according to BPA. During a July 2017 heatwave, a combination of high electricity use and equipment failures came close to triggering load shedding — interrupting the flow of electricity to prevent overloading the grid. BPA has developed procedures since then to reduce that risk, but 'the situation remains tenuous,' according to the BPA's draft environmental assessment determination for the South of Tri-Cities Reinforcement Project. BPA expects the greater Tri-Cities area to reach the 1,100 megawatts threshold with increasing frequency as the demand for electricity continues to grow over the next decade, putting long-term reliability of the grid at risk, the draft assessment said. Taking one BPA line serving the Tri-Cities area out of service for regular maintenance also increases chances that other lines become overloaded. As a result, maintenance of BPA systems has been put off, increasing the risk of equipment failure, the draft assessment said. Now maintenance must be avoided during high demand times — both the heat of summer and cold of winter — and also when there are seasonal restrictions on producing hydropower to help endangered salmon. Clean energy development and data centers in the area also would be addressed by the proposed new transmission project. Requests to integrate new power generation sources, such as wind and solar projects like the Horse Heaven Clean Energy Center, into BPA's transmission system are contributing to anticipated capacity issues in the greater Tri-Cities area, the draft assessment said. And data center demands from the Boardman and Umatilla, Ore., areas are increasing the strain on the transmission lines through the greater Tri-Cities area, according to the draft assessment. The 66% increase in BPA's transmission capacity to the Tri-Cities area would be welcomed by business interests. The Tri-Cities needs significantly more transmission capacity if it is going to attract large industrial projects that offer family wage jobs, said David Reeploeg, a Tri-City Development Council vice president. TRIDEC supports the proposed transmission project. The project also is important to support the future growth of Pacific Northwest National Laboratory based in Richland, Reeploeg said. The Department of Energy lab has a $1.6 billion annual research budget and about 6,400 employees. It also could help Atlas Agro, which is considering the Tri-Cities for its $1.1 billion green fertilizer plant, and needs the transmission project completed before it moves forward, he said. 'In the short term, it provides a significant addition to the regional capacity,' Reeploeg said. It would support industrial projects underway or planned now and provide some additional margin to attract new industrial projects, he said. But long term TRIDEC wants the additional generation that would be provided by advanced nuclear projects to meet power production demand created by Washington state's decarbonization goals, companies looking for large electric loads for data centers and new large industries, he said. Public comments submitted to BPA on the proposed project have focused on support for the project and concerns about the location of the project from the Leslie Road Substation in Richland to several miles to the west. BPA is considering one route for that section of the project that would follow railroad tracks from near Kennewick's Cottonwood Elementary along East Badger Road. A second alternative to the north of East Badger Road would parallel the north side of a Kennewick Irrigation District canal. The draft environmental assessment of the project found the railroad route to be the best option, but BPA is not bound to that recommendation. The railroad option would disturb less vegetation and wildlife than the canal option's route through 680 acres of high quality shrub steppe habitat, the draft assessment found. Landowners along the canal option route have opposed that option, saying some of their land would be needed for the project. It includes part of the six acres where Linda Utley has a greenhouse and other farming operations to grow plants, berries and florals for her shop, the Badger Canyon Tea Co. in Kennewick. The Utleys have lived in Badger Canyon for more than 50 years, the last 30 years at their current location. The Utley home would be 250 feet from transmission lines, which would run along two sides of her property because the route turns there, she said. Humming from the lines could create a sound problem, she said, Arleen Fetrow said her house would be even closer at 150 feet from transmission lines. Utley is also concerned about preserving 250 30-year-old Austrian pines that line the private gravel road that provides access to homes along that section of the canal. The public can comment on the transmission line project's draft environmental assessment, including whether it should use the railroad or canal route, until June 21. Call 800-622-4519 or post online at Written comments may be sent to Bonneville Power Administration; Communications – DKS-7; P.O. Box 14428; Portland, OR 97291-4428.
